Aytu Biopharma (AYTU) Share-based Compensation (2014 - 2026)

Aytu Biopharma (AYTU) has reported Share-based Compensation for 13 consecutive years, with $203744.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Share-based Compensation fell 7.07% year-over-year to $203744.0 in Q1 2026; TTM through Mar 2026 was $203744.0, a 7.07% decrease from a year earlier, with the FY2025 full-year figure at $576000.0, down 80.23% from the prior year.
• Share-based Compensation was $203744.0 for Q1 2026 at Aytu Biopharma, down from $283000.0 in the prior quarter.
• Over five years, Share-based Compensation peaked at $3.1 million in Q4 2022 and troughed at $113000.0 in Q2 2025.
• A 5-year average of $757598.8 and a median of $811000.0 in 2024 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation surged 36331.44% in 2022 and sank 81.4% in 2024, its largest moves.
• Over 5 years, Share-based Compensation stood at $3.1 million in 2022, then plunged by 73.26% to $820000.0 in 2023, then sank by 73.0% to $221392.0 in 2024, then grew by 27.83% to $283000.0 in 2025, then slipped by 28.01% to $203744.0 in 2026.
• The last three Share-based Compensation figures came in at $203744.0 (Q1 2026), $283000.0 (Q4 2025), and $206800.0 (Q3 2025), per Business Quant data.